Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10167)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
GSK3B
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2) [Suppressor; Marker]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Responsed Drug | Nobiletin | Investigative | ||
Pathway Response | Pathways in cancer | hsa05200 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 |
Response regulation | Nobiletin could induce ferroptosis by regulating the GSK3B-mediated Keap1/Nrf2/HO-1 signalling pathway in human melanoma cells. Hence, nobiletin stands as a promising drug candidate for melanoma treatment with development prospects. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Intracerebral hemorrhage | ICD-11: 8B00 | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Wnt signaling pathway | hsa04310 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNs (Rat primary neurons) | ||||
In Vivo Model |
C57BL/6 J pregnant mice (E15 ~ E16 day) were disinfected with 75% alcohol and then decapitated. The brain was collected and washed in pre-cold D-Hanks solution with the midbrain and hippocampus being removed. The cortex was collected and the meninx was removed. Then the brain tissues were made into 1 mm3 blocks for digestion with 1 ~ 2 mL lysis at 37 for 15 min. The tissues were cultured in high glucose DMEM to terminate the digestion and made into single-cell suspension. The suspension was filtered through a 70 um mesh screen for centrifugation for 5 min with the supernatant being removed. High glucose DMEM was used to re-suspended cells and the concentration of cells was adjusted for cells were seeded into the plate. About 4 h later, the high glucose DMEM was replaced with Neurobasal medium (containing 2% B27). The culture medium was half refreshed every 2 ~ 3 d. The cells were cultured for 8 ~ 10 d before following experiments.
Click to Show/Hide
|
||||
Response regulation | Treatment of miR-1405p mimics led to decreased COX-2 and ACSL4 expressions, and elevated GPX-4 expressions. circAFF1 can bind miR-1405p to up-regulate GSK-3 expression, thus inhibiting the Wnt/-catenin signaling pathway. And circAFF1 knockdown can suppress ferroptosis of neurons in vitro and therefore attenuate intracerebral hemorrhage (ICH). | ||||
Melanoma [ICD-11: 2C30]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Glycogen synthase kinase-3 beta (GSK3B) | Protein coding | ||
Responsed Drug | Nobiletin | Investigative | ||
Pathway Response | Pathways in cancer | hsa05200 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 |
Response regulation | Nobiletin could induce ferroptosis by regulating the GSK3B-mediated Keap1/Nrf2/HO-1 signalling pathway in human melanoma cells. Hence, nobiletin stands as a promising drug candidate for melanoma treatment with development prospects. | |||
Intracerebral hemorrhage [ICD-11: 8B00]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | ||||
Target Regulator | Glycogen synthase kinase-3 beta (GSK3B) | Protein coding | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Wnt signaling pathway | hsa04310 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model |
rPNs (Rat primary neurons) | ||||
In Vivo Model |
C57BL/6 J pregnant mice (E15 ~ E16 day) were disinfected with 75% alcohol and then decapitated. The brain was collected and washed in pre-cold D-Hanks solution with the midbrain and hippocampus being removed. The cortex was collected and the meninx was removed. Then the brain tissues were made into 1 mm3 blocks for digestion with 1 ~ 2 mL lysis at 37 for 15 min. The tissues were cultured in high glucose DMEM to terminate the digestion and made into single-cell suspension. The suspension was filtered through a 70 um mesh screen for centrifugation for 5 min with the supernatant being removed. High glucose DMEM was used to re-suspended cells and the concentration of cells was adjusted for cells were seeded into the plate. About 4 h later, the high glucose DMEM was replaced with Neurobasal medium (containing 2% B27). The culture medium was half refreshed every 2 ~ 3 d. The cells were cultured for 8 ~ 10 d before following experiments.
Click to Show/Hide
|
||||
Response regulation | Treatment of miR-1405p mimics led to decreased COX-2 and ACSL4 expressions, and elevated GPX-4 expressions. circAFF1 can bind miR-1405p to up-regulate GSK-3 expression, thus inhibiting the Wnt/-catenin signaling pathway. And circAFF1 knockdown can suppress ferroptosis of neurons in vitro and therefore attenuate intracerebral hemorrhage (ICH). | ||||
Nobiletin
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Nuclear factor erythroid 2-related factor 2 (NFE2L2) | Suppressor; Marker | ||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Pathway Response | Pathways in cancer | hsa05200 | ||
Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
SK-MEL-28 cells | Cutaneous melanoma | Homo sapiens | CVCL_0526 |
Response regulation | Nobiletin could induce ferroptosis by regulating the GSK3B-mediated Keap1/Nrf2/HO-1 signalling pathway in human melanoma cells. Hence, nobiletin stands as a promising drug candidate for melanoma treatment with development prospects. | |||
References